Anti-deltaNp63 [PANp63-6.1]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-deltaNp63 [PANp63-6.1]
• Clone: PANp63-6.1
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Molecular weight: 72-76 kDa (variable, depending on the p63 isoform present)
• Reactivity: Human ; mouse ; rat
• Host: Mouse
• Description: Antibody created to detect the deltaN isoform of p63 (deltaNp63) with tumour suppressor role and differentiate from the TA (TAp63) isoforms of the same protein. Binding specificity: Epitope mapping using phage display identified the epitope PSHLIR, which occurs twice within the central region of p63. The antibody recognizes TAp63 and deltaNp63. The antibody does not cross-react with p53 or any p73 isoform tested.
• Immunogen: PSHLIR sequence of tumour protein p63 (deltaN isoform)
• Isotype: IgG1 kappa
• Production details: B cell donor: Splenocytes from mouse immunised with recombinant TAp63?, Fusion partner: SP2

Target Details

• Target: tumour protein p63 lacking the transactivation domain (TA)
• Molecular weight: 72-76 kDa (variable, depending on the p63 isoform present)
• Target background: p63 is a transcription factor of the p53 gene family, encoded by the TP63 gene located at chromosome 3q28. p63 exists as N-terminal isoforms that either contain (TAp63) or lack (deltaNp63) the p53-like transactivation domain at the N-terminus. C-terminal isoforms are produced by alternative splicing of 3' exons. TAp63 is involved in germ cell maintenance and myocyte differentiation, and is expressed in some lymphocytes and lymphomas/leukemias.
• Epitope sequence: PSHLIR

Handling

• Format: Liquid
• Shipping conditions: Dry ice

References

• Nekulova et al. 2013. Virchows Arch. Sep:463(3):415-25. PMID: 23887585
• Liu et al. 2020. J Pathol Clin Res. Jan:6(1):83-93. PMID: 31591823
• Galoczova et al. 2021. Virchows Arch. Apr:478(4):627-636. PMID: 33037932
• Stenckova et al. 2023. Neoplasma Oct:70(5):621-632. PMID: 38053383